Global On-body Injectors Market Strategic Research Report

Scope of the Report

The global On-body Injectors market size is predicted to grow from US$ 213 million in 2025 to US$ 600 million in 2032; it is expected to grow at a CAGR of 16.2% from 2026 to 2032.

On-body injectors, also known as on-body delivery systems (OBDS), are medical devices designed to deliver a controlled dose of medication or therapeutic substances subcutaneously (under the skin) over a specified period. These devices are typically worn on the body and are used to administer various treatments, including medications, hormones, and biologics. On-body injectors offer several advantages, including increased patient convenience, improved medication adherence, and the ability to deliver complex therapies. The scope of this report is non-insulin On-body injectors.

In 2024, the global sales ofnon-insulin on-body injectorsreached approximately5 million units, with an average market price of$35 per unit.

North America is currently the largest market for on-body injectors, driven by high healthcare spending, early adoption of advanced drug delivery technologies, and a strong presence of key players such as Amgen (with its Neulasta® Onpro® kit). The United States leads in the development and approval of wearable drug delivery systems, especially for chronic conditions like cancer and autoimmune diseases. Growing demand for home-based treatment and reduced hospital visits post-COVID-19 has further accelerated market expansion.

Europe is a strong and steadily growing market for on-body injectors, supported by rising prevalence of chronic diseases, aging populations, and robust healthcare infrastructure. Countries such as Germany, the UK, and France are key adopters, with regulatory support for patient-centric drug delivery systems. The focus on reducing hospital burden and improving patient compliance is encouraging healthcare providers to adopt wearable injectors, particularly for biologics and long-term therapies.

Asia-Pacific is the fastest-growing region for on-body injectors, driven by increasing healthcare awareness, expanding middle-class populations, and rising chronic disease incidence. Countries like China, Japan, and South Korea are investing heavily in digital health and self-administered therapies.

This report presents a comprehensive overview of the global On-body Injectors market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Electronic Injectors
• Mechanical Injectors

Segment by Application

• Immuno-oncology
• Cardiovascular Diseases
• Neurological Diseases
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global On-body Injectors market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Immuno-oncology, Cardiovascular Diseases, Neurological Diseases evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact